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Abstract
In Gaucher disease patients, over 100 disease-causing mutations have been identified. For identification of the 1504CCT
(R463C) mutation it is common to use PCR-restriction fragmentation analysis using the restriction enzyme MspI. In the
present study we investigated the reliability of this approach because accurate determination of genotypes is important in
genotype-phenotype correlations. A simple modification, i.e. using the restriction enzyme HphI instead of MspI, revealed
that type I and II Gaucher disease patients who had previously been identified as carrying the 1504CCT mutation in fact
carried the 1505GCA (IVS1031GCA) mutation. Sequencing of the appropriate fragment confirmed this. The PCR method
easily differentiates between these two mutations in Gaucher disease patients, thus circumventing the need for sequencing
procedures. The phenotypes of the patients found to be carrying the 1505GCA mutation are also described. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
Gaucher disease is the most frequent lysosomal
storage disease and results from the de¢cient activity
of the lysosomal enzyme L-glucocerebrosidase (EC
3.2.1.45). It exhibits marked clinical heterogeneity
and on the basis of the presence and progression of
neurological involvement three main types have been
described, i.e. types I, II and III [1].
Up to date more than 100 disease-causing mu-
tations have been identi¢ed in the gene encoding
L-glucocerebrosidase (GBA), located on chromo-
some 1q21 [2,3]. Although PCR techniques followed
by restriction fragmentation analysis are often used
in the identi¢cation of mutations, their accuracy is
limited by the fact that they often cannot distinguish
between di¡erent mutations within the recognition
site of the restriction enzyme used and also, in
some cases, cannot di¡erentiate between point muta-
tions and deletions [4^6].
Over the last 18 years, 43 Greek patients with
Gaucher disease have been diagnosed in our labora-
tory. All cases were routinely screened for four mu-
tations, 1226ACG (N370S), 1448TCC (L444P),
1342GCC (D409H) and 1504CCT (R463C), using
PCR and restriction fragmentation analysis. These
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four mutations cover 78% of the studied alleles (Mi-
chelakakis, unpublished observation).
In the present study we investigated the reliability
of the identi¢cation of the 1504CCT mutation in
our Gaucher patients based upon the PCR-restric-
tion fragmentation method commonly employed
that uses the restriction enzyme MspI [7,8]. A simple
modi¢cation of this method, using the restriction en-
zyme HphI instead of MspI, revealed that all patients
previously identi¢ed as carrying the 1504CCT mu-
tation in fact carried the 1505GCA (IVS1031GCA)
[9] mutation. This was con¢rmed by direct sequenc-
ing of the appropriate PCR fragments.
2. Materials and methods
2.1. Gaucher patients
Four Greek patients were studied, three belonging
to type I and one to type II. A Surinam patient,
living in The Netherlands and carrying the
1504CCT (R463C) mutation was included as a con-
trol.
2.2. Enzyme assays
The activities of L-glucosidase from white blood
cells and chitotriosidase from plasma were assayed
using their 4-methylumbelliferyl substrates [7,10].
2.3. Analysis of L-glucocerebrosidase mutations
Genomic DNA was isolated from white blood cells
using the standard phenol-extraction procedure [7,8].
Mutational analysis was carried out using PCR am-
pli¢cation of appropriate fragments of the genomic
DNA, followed by restriction fragmentation analysis.
The primers used were manufactured by the Micro-
chemistry Lab FORTH (Greece). Restriction en-
zymes HphI, XhoI, StyI, NciI and MspI were from
New England Biolabs (Beverly, MA, USA). Master
Amp Taq DNA polymerase was from Epicentre
Technologies (Madison, WI, USA).
2.4. Restriction fragmentation analysis
The 1226ACG (N370S) mutation was analysed
using mismatched PCR, as described by Beutler et
al. [11].
The same upstream and downstream primers were
used for analysis of the 1448TCC (L444P),
1342GCC (D409H), 1504CCT (R463C) and
1505GCA (IVS1031GCA) mutations, but the
products were digested with di¡erent restriction en-
zymes [8]. For the detection of 1342GCC and
1448TCC the restriction enzymes StyI and NciI
were used, respectively [8].
The restriction enzyme MspI has been used for the
detection of 1504CCT [8], but it does not discrim-
inate for the presence of 1505GCA. Therefore, the
restriction enzyme HphI was used in parallel for the
detection of 1505GCA. Digestion was carried out
overnight at 37‡C. The HphI reaction mixture was
loaded on a 10% polyacrylamide gel, electrophoresed
and visualised by staining with ethidium bromide.
2.5. Direct sequencing
For the sequencing analysis, a 708 bp fragment
was generated using the PCR technique with the up-
stream and downstream primers for the 1448TCC
mutation [8]. The PCR fragment was isolated from a
1% agarose gel and subsequently sequenced as fol-
lows. The PCR fragment (10 ng) was incubated with
1.6 pmol of 1448TCC downstream primer and 4 Wl
of BigDye Terminator Ready Reaction mix (includ-
ing AmpliTaq Polymerase FS, bu¡er and £uorescent
nucleotides) in a total volume of 10 Wl. The cycling
sequence was run for 25 cycles. The DNA was pre-
cipitated, dissolved in 1.5 Wl loading bu¡er (deionised
formamide: 25 mM EDTA (pH 8.0), containing 50
ng/ml Blue dextran, in a ratio of 5:1) and analysed
on an ABI Prism 377 sequencer (Perkin-Elmer, Fos-
ter City, CA, USA).
3. Results and discussion
The frequency of mutations at codon 463 of the
GBA gene di¡ers in di¡erent populations. So far
they have not been encountered in Jewish and Dutch
Gaucher patients [2,8], but they are reported to occur
with high frequency in British and Irish patients [5].
In our Greek population they were found in four out
of the 86 studied Gaucher disease alleles (5%), ac-
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counting for 6% of the identi¢ed mutations in our
patients (n = 43) (Michelakakis, unpublished data).
So far two di¡erent nucleotide substitutions have
been described that a¡ect codon 463, i.e. those occur-
ring either at the penultimate or at the ultimate nu-
cleotides of exon 10 of the GBA gene. The former is
a CCT transition at position 1504 of the cDNA and
results in an R463C substitution [12]. The latter is a
GCA transition at position 1505 of the cDNA ¢rst
described by Oshima et al. [9]. In their study they
showed that the mutation caused altered splicing.
In particular, it was shown that the normal 5P splic-
ing site ‘gt’ was not recognised and the next ‘gt’ in
intron 10 was instead recognised as a splicing donor
site in the mutant allele. This resulted in a 12 bp
insertion in the mRNA downstream from codon
463, that resulted in an R463Q substitution and a
new stop codon at codon 464.
Although the 1505GCA substitution is a splicing
mutation, it is often referred to in the literature as
the ‘missense mutation R463Q’, which can result in
confusion with respect to its nature and identity [2].
MspI digestion of exon 10 has been proposed as
an easy method for screening for the 1505GCA
mutation [13,14]. However, MspI digestion cannot
di¡erentiate between mutations 1505GCA and
1504CCT, since the PCR products from both mu-
tant alleles do not have the sequence which MspI
recognises (CCGG). On the other hand, the restric-
tion site GGTGA of HphI is present in both the wild
type and the 1504CCT, but not in the 1505GCA
PCR products. Digestion of the PCR products with
HphI results in ¢ve fragments in the case of the
1505GCA mutation (45 bp, 74 bp, 90 bp, 198 bp
and 300 bp) and in six fragments in the case of the
wild type sequence or the 1504CCT mutation (12 bp,
45 bp, 74 bp, 90 bp, 186 bp, 300 bp). Using HphI in
the restriction fragmentation analysis of PCR prod-
ucts from our patients, the pattern observed was that
expected for 1505GCA (IVS1031GCA) (Fig. 1).
According to our results, our patients previously
identi¢ed as carrying the 1504CCT (R463C) muta-
tion were in fact carrying the 1505GCA
(IVS1031GCA) mutation. In order to verify the
presence of the latter mutation, sequencing of the
appropriate fragment was carried out as described
in Section 2. The results obtained con¢rmed the pres-
Fig. 1. HphI restriction analysis for the detection of 1505GCA
(IVS1031GCA) mutation. M, xX174 DNA/HinfI marker;
A, B, C, D, Greek patients; E, Surinam patient carrying the
1504CCT (R463C) mutation; WT, normal individual. The
sizes (bp) of the relevant digestion products are indicated.
Table 1
Clinical characteristics, L-glucosidase and chitotriosidase activity and mutations identi¢ed in the patients studied
Patient Age at
diagnosis
Main clinical
manifestation
White blood cell L-glucosidase
activity (control range:
6^23 nmoles/mg protein/h)
Plasma chitotriosidase
activity (control range:
0^150 nmoles/ml/h)
Genotype
Type I years
A 11 S 1.3 0 N370S/IVS1031GCA
B 20 HS, Thr, BI 1.2 18 293 N370S/IVS1031GCA
C 35 HSa, Thr, BIa 1.8 5 904 N370S/IVS1031GCA
Type II days
D 30 HS, NI, HyB 0.9 3 018 D409H/IVS1031GCA
S, splenomegaly; HS, hepatosplenomegaly; Thr, thrombocytopenia; BI, bone involvement; HyB, hyperbilirubinaemia; NI, neurologi-
cal involvement.
aMild.
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ence of the 1505GCA substitution in our patients
(Fig. 2).
Expression studies have shown that the 1504CCT
(R463C) mutant enzymic protein shows some impair-
ment of its speci¢c activity (about 40% residual ac-
tivity), normal inhibition patterns by conduritol B
epoxide and glucosylsphingosine, but reduced sus-
ceptibility to activation by both saposin C and phos-
phatidylserine [15]. The mutation had been identi¢ed
in the heterozygote state in patients with all types of
Gaucher disease, whereas in the homozygote state it
was recently described in a severe type III patient
from Turkey [16^18]. However, since most of these
studies were carried out using digestion of PCR-am-
pli¢ed fragments with MspI as the restriction en-
zyme, it is essential that accurate determination of
the mutation at codon 463 is achieved before any
genotype-phenotype correlations are made. In fact,
when they were reexamined using sequencing of the
PCR fragments, some of the published cases were
shown to carry the 1505GCA (IVS1031GCA) mu-
tation. So far, this latter mutation, which leads to
Fig. 2. Automated sequencing of genomic DNA identifying the1505GCA (IVS1031GCA) (patients A, B, C, D) and 1504CCT
(R463C) (patient E) mutations, using an antisense primer. The position of the mutations is indicated by an arrow. In red are the rele-
vant base pair changes.
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premature termination of protein synthesis and thus
is more severe than the 1504CCT (R463C) muta-
tion, has been reported only in the heterozygote state
in very few patients with types I, II and III of
Gaucher disease [5,9,13]. Recently, the mutation in
combination with RecNciI was described in a case of
lethal prenatal Gaucher disease [19]. In our cases, it
was found in type I and type II patients and di¡er-
ences were noted in the severity of the clinical ex-
pression of the N370S/IVS1031GCA genotype.
Thus, patient A had an earlier onset of symptoms
than either patient B or C. Patients B and C are
siblings, but patient C, with a much milder clinical
presentation and lower plasma chitotriosidase levels,
was diagnosed at the age of 35 years, only after the
diagnosis of her 20 year old brother had been estab-
lished (Table 1). All three type I patients carrying the
IVS1031GCA mutation originate from the same
area of Greece, around Epidaurus. It is of interest
that our type II case had the same genotype (i.e.
D409H/IVS1031GCA) as the type III Japanese
case in whom the IVS1031GCA mutation was orig-
inally described [9].
Cloning of the GBA gene has led to the identi¢-
cation of more than 100 mutations in Gaucher dis-
ease patients [2,3]. Accurate determination of indi-
vidual mutations is important in studies of
genotype-phenotype correlations. Our paper de-
scribes an easily applicable PCR method that di¡er-
entiates between the 1504CCT (R463C) and the
1505GCA (IVS1031GCA) mutations in Gaucher
disease patients, thus circumventing sequencing pro-
cedures that are not widely available.
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